What is the effect of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on cardiovascular disease (CVD) prevention, and how does dosage influence this effect?
Omega-3 EPA/DHA Fish Oil, a meta-analysis (Mayo Clin Proc 2020, PMID 32951855) — supplementation was associated with a reduced risk of MI (RR, 0.87), CHD events (RR, 0.90), fatal MI (RR, 0.65), and CHD mortality (RR, 0.91). No significant reduction was observed for overall CVD events (RR, 0.95).
Source: Mayo Clin Proc 2020, PMID 32951855 ↗ · Research map · How Magellan grades evidence · evidence confidence: high
Mayo Clin Proc · 2020 · PMID 32951855 · DOI 10.1016/j.mayocp.2020.08.034
Omega-3 fatty acid supplementation can reduce the risk of certain cardiovascular events, with greater benefits potentially seen at higher doses.
The question
What is the effect of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on cardiovascular disease (CVD) prevention, and how does dosage influence this effect?
What they tested
The study implicitly hypothesizes that EPA/DHA supplementation will reduce the risk of cardiovascular events and that this effect may be dose-dependent.
How they did it
This study is a random effects meta-analysis and meta-regression of randomized controlled trials (RCTs) involving EPA/DHA supplementation and cardiovascular outcomes. It included RCTs published before August 2019, covering outcomes such as myocardial infarction (MI), coronary heart disease (CHD) events, CVD events, CHD mortality, and fatal MI. The Grading of Recommendations Assessment, Development, and Evaluation framework was used to assess the strength of evidence.
What they found
Forty studies with 135,267 participants were included. Supplementation was associated with a reduced risk of MI (RR, 0.87), CHD events (RR, 0.90), fatal MI (RR, 0.65), and CHD mortality (RR, 0.91). No significant reduction was observed for overall CVD events (RR, 0.95). The protective effect was found to be dose-dependent for CVD events and MI.
| Myocardial Infarction (MI) | 0.87 | |
|---|---|---|
| Coronary Heart Disease (CHD) Events | 0.9 | |
| Fatal MI | 0.65 | |
| CHD Mortality | 0.91 | |
| CVD Events (composite) | 0.95 |
Relative risk (RR) for various cardiovascular outcomes with EPA/DHA supplementation. An RR less than 1 indicates a reduced risk.
What it means
Supplementation with EPA and DHA is an effective lifestyle strategy for CVD prevention, and the protective effect likely increases with dosage.
Limitations
The abstract does not explicitly state limitations of the study, but as a meta-analysis, it is dependent on the quality and reporting of the included individual studies.
Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.
The paper at a glance
| Title | Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis of Interventional Trials |
|---|---|
| Journal | Mayo Clin Proc |
| Year | 2020 |
| PMID | 32951855 ↗ |
| DOI | 10.1016/j.mayocp.2020.08.034 ↗ |
| Topic | Cardiovascular & vascular aging |
Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗
Where Magellan uses this paper
This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.
Omega-3 EPA/DHA Fish Oil
Across large randomized trials and meta-analyses, marine omega-3s reliably reduce serum triglycerides (roughly 15% at higher doses) and modestly lower blood pressure and resting heart rate, but their effect on cardiovascular events is mixed and depends on dose, formulation and population.
Omega-3 fatty acids are long-chain polyunsaturated fats, principally eicosapentaenoic acid (EPA) and…
Research describes the compound or intervention studied. It is not a claim about any specific product.
Molecules & mechanisms in this paper
Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.
Cite this page
These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.
Magellan Longevity. (2026). What is the effect of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on cardiovascular disease (CVD) prevention, and how does dosage influence this effect? [Plain-English summary of Mayo Clin Proc 2020, PMID 32951855, DOI 10.1016/j.mayocp.2020.08.034]. Magellan Longevity. https://magellanlongevity.com/study/d32951855.html@misc{magellan_d32951855,
title = {What is the effect of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on cardiovascular disease (CVD) prevention, and how does dosage influence this effect?},
author = {{Magellan Longevity}},
year = {2026},
howpublished = {\url{https://magellanlongevity.com/study/d32951855.html}},
note = {Plain-English summary of PubMed PMID 32951855; DOI 10.1016/j.mayocp.2020.08.034; Mayo Clin Proc 2020. Reviewed by Gabriel Radu, DO},
urldate = {2026-08-11}
}https://magellanlongevity.com/study/d32951855.htmlRelated studies in the Magellan library
- What are the effects of increased intake of fish- and plant-based omega-3 fats (LCn3 and ALA)…Cochrane Database Syst Rev · 2020 · PMID 32114706
- Effect of omega-3 fatty acids on cardiovascular outcomesEClinicalMedicine · 2021 · PMID 34505026
- Omega-3 fatty acids and mortality in patients referred for coronary angiographyAtherosclerosis · 2016 · PMID 27397734
- What is the significance of the erythrocyte EPA+DHA percentage (Omega-3 Index) for brain…Nutrients · 2021 · PMID 33806218
- Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with…Nutrients · 2022 · PMID 36235651
- Effect of quercetin supplementation on plasma lipid profiles, blood pressure, and glucose levelsNutr Rev · 2020 · PMID 31940027
All 67 Magellan summaries on cardiovascular & vascular aging →
Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →